Biologic Therapies III
RA and Granulomatous Infection
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: April 21, 2010
Expiration Date: April 21, 2012
Estimated Time of Completion: 15 minutes
Description
The Biologics Therapies Summit III Mini-Symposium Master Clinician Panel was captured and repurposed into a case-based format to discuss the management strategies for clinicians caring for patients with rheumatic and inflammatory diseases. The cases include autoimmune and inflammatory disorders, common and rare infections associated with biologics, newer agents, and biologic use with existing conditions such as, cancer, and liver disease.
Objectives
After completing this activity, the participant will be able to do the following:
- Recognize the types of disease and drug-related granulomatous infections occurring in RA.
- Identify strategies to reduce the risk of granulomatous and opportunistic infections.
Target Audience
This case-based series is directed toward rheumatologists, gastroenterologists, dermatologists, pulmonologists, internal medicine physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in or using biologic therapeutics in autoimmune and inflammatory disorders.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University
Vice Chairman,
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Orthopaedic & Rheumatologic Institute
Cleveland Clinic
Authors
| Leonard Calabrese, DO Professor of Medicine Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Vice Chairman, Department of Rheumatic & Immunologic Diseases R.J. Fasenmyer Chair of Clinical Immunology Orthopaedic & Rheumatologic Institute Cleveland Clinic |
John Cush, MD Director of Clinical Rheumatology Baylor Research Institute Dallas, TX |
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship that, in the context of their presentations, could be perceived as a potential conflict of interest:
| Leonard Calabrese, DO | ||
| Consulting |
Elan; Roche |
|
| Consulting, Teaching & Speaking |
Abbott; Amgen; Centocor; Genentech; Wyeth |
|
| John Cush, MD | ||
| Clinical Investigator: |
CORRONA; Celgene; Genentech, Pfizer; Roche; UCB | |
| Consulting: |
Abbott; Centocor; Pfizer; Roche; UCB; Wyeth/Amgen | |
| Membership on Advisory Committee/Review Panels: |
Wyeth/Amgen | |
| Teaching & Speaking: |
Abbott | |
The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational
grants for partial support of this activity from:
Abbott Laboratories, Amgen, Centocor Ortho Biotech, Genetech and Biogen Idec,
Roche Laboratories, Inc., UCB, Inc., Wyeth
This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education
and
the RJ Fasenmyer Center for Clinical Immunology.
